BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29194093)

  • 1. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.
    Xerri L; Adélaïde J; Popovici C; Garnier S; Guille A; Mescam-Mancini L; Laurent C; Brousset P; Coze C; Michel G; Chaffanet M; Bouabdallah R; Coso D; Bertucci F; Birnbaum D
    Am J Surg Pathol; 2018 Feb; 42(2):150-159. PubMed ID: 29194093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case of Pulmonary Langerhans Cell Sarcoma Simultaneously Diagnosed with Cutaneous Langerhans Cell Histiocytosis Studied by Whole-Exome Sequencing.
    Kim SW; Choi MK; Han HS; Song H; Koh Y; Son SM; Lee OJ; Lee JY; Lee KM; Lee KH; Kwon J
    Acta Haematol; 2017; 138(1):24-30. PubMed ID: 28614815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
    McGinnis LM; Nybakken G; Ma L; Arber DA
    Am J Surg Pathol; 2018 Jul; 42(7):885-890. PubMed ID: 29649018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
    Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
    Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms.
    Huang W; Qiu T; Zeng L; Zheng B; Ying J; Feng X
    Oncotarget; 2016 Nov; 7(48):78355-78362. PubMed ID: 27823979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.
    Martinez D; Navarro A; Martinez-Trillos A; Molina-Urra R; Gonzalez-Farre B; Salaverria I; Nadeu F; Enjuanes A; Clot G; Costa D; Carrio A; Villamor N; Colomer D; Martinez A; Bens S; Siebert R; Wotherspoon A; Beà S; Matutes E; Campo E
    Am J Surg Pathol; 2016 Feb; 40(2):192-201. PubMed ID: 26426381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
    Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
    Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion.
    Cheaney B; Bowden S; Krause K; Sloan EA; Perry A; Solomon DA; Han SJ; Wood MD
    Acta Neuropathol Commun; 2019 Jul; 7(1):110. PubMed ID: 31288852
    [No Abstract]   [Full Text] [Related]  

  • 12. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
    Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
    Allen CE; Parsons DW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Langerhans Cell Sarcoma in a Chronic Myelogenous Leukemia Patient Undergoing Imatinib Mesylate Therapy: A Case Study and Review of the Literature.
    Chang NY; Wang J; Wen MC; Lee FY
    Int J Surg Pathol; 2014 Aug; 22(5):456-63. PubMed ID: 24008437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Langerhans cell sarcoma with lineage infidelity/plasticity: a diagnostic challenge and insight into the pathobiology of the disease.
    Karai LJ; Sanik E; Ricotti CA; Susa J; Sinkre P; Aleodor AA
    Am J Dermatopathol; 2015 Nov; 37(11):854-61. PubMed ID: 26368646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.